|Bid||4.3200 x 900|
|Ask||4.4400 x 900|
|Day's range||4.3000 - 4.4250|
|52-week range||3.4600 - 13.0000|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2021 - 16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.00|
SAN DIEGO, Jun 15, 2021--Biocept received more than 420,000 samples for COVID-19 testing since launching service in June 2020.
Biocept and CLEARED4 to develop new system for tracking and managing COVID-19 testing for campuses and other facilities returning to full capacity.
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).